Suppr超能文献

己酸羟孕酮、他莫昔芬及其联合用药对子宫内膜癌患者肿瘤中甾体激素受体水平及生殖系统某些参数的影响。

Effect of oxyprogesterone caproate, tamoxifen and their combination on the level of steroid hormone receptors in the tumor, and some parameters of the reproductive system in patients with endometrial cancer.

作者信息

Vishnevsky A S, Shtofmakher J A, Bokhman J V, Tsyrlina E V, Bobrov J F, Chepick O F, Sofroniy D F

机构信息

Petrov Research Institute of Oncology, Leningrad, USSR.

出版信息

Clin Exp Obstet Gynecol. 1990;17(3-4):159-62.

PMID:2127240
Abstract

The results of preoperative use of oxyprogesterone caproate (OPC), Tamoxifen and their combination in 165 patients suffering from primary endometrial carcinoma are presented. It was shown that Tamoxifen was able to increase concentrations cytoplasmatic receptors to progesterone in the tumor. The incidence of specific hormonal pathomorphosis in the tissue of the tumor in patients who received a combination of OPC and Tamoxifen was significantly higher (80% of cases) as compared to the separate use of OPC (60%) or Tamoxifen (57%).

摘要

本文呈现了165例原发性子宫内膜癌患者术前使用己酸羟孕酮(OPC)、他莫昔芬及其联合用药的结果。结果表明,他莫昔芬能够提高肿瘤细胞中孕激素的细胞质受体浓度。与单独使用OPC(60%)或他莫昔芬(57%)相比,接受OPC和他莫昔芬联合用药的患者肿瘤组织中特定激素病理形态的发生率显著更高(80%的病例)。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验